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A
 
BSTRACT
 
The induction of allergen-specific IgE synthesis requires
the cognate interactions between B and T helper (Th)
2 cells. The B cell-activating signal for IgE synthesis is
delivered through interleukin (IL)-4 or IL-13 and CD40
ligand, which are provided by activated Th2 cells.
Signaling through the IL-4 receptor 
 
α
 
 chain (IL-4R
 
α
 
)
triggers IL-4- or IL-13-dependent germline C
 
ε
 
 tran-
scription by activating signal transducer and activator
of transcription (STAT)-6 through members of the
Janus kinase (JAK) family. In addition to the known
JAK–STAT pathway, two adaptor molecules associated
with the IL-4R
 
α
 
, which include Src homologous and
collagen (Shc) and a product of the 
 
fes
 
 proto-oncogene
family, are involved in the induction of germline C
 
ε
 
transcription. These adaptor molecules transmit the
downstream signaling, leading to activation of PU.1, a
product of the 
 
ets
 
 proto-oncogene family, which co-
operates functionally with STAT-6 for germline C
 
ε
 
transcription. Ligation of CD40 in the presence of IL-4
or IL-13 leads to expression of activation-induced cyti-
dine deaminase (AID). This novel RNA-editing enzyme
plays a role upstream of the putative switch recom-
binase, activation of which results in IgE isotype
switching, mature C
 
ε
 
 transcription and IgE synthesis.
Although CD40 signaling activates multiple pathways
that are critical for the activation of the switch recom-
bination machinery, none of the known second
messengers and transcription factors generated by
CD40 ligation is involved in AID expression and
isotype switching. Elucidation of the merging point of
IL-4R
 
α
 
 and CD40 signaling pathways required for IgE
switching will provide potential new strategies for the
isotype-specific regulation of IgE synthesis.
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I
 
NTRODUCTION
 
The human immunoglobulin family consists of nine
isotypes, each of which is involved in humoral immunity.
Of these isotypes, IgE plays a key role in the patho-
genesis of allergic disease. The production of IgE by
B cells requires interactions with T cells and is induced
through cytokines and cell surface molecules provided by
activated T cells. Increasing understanding of the cellular
and molecular events underlying IgE synthesis has
allowed the identification of new targets for IgE regula-
tion. The present article provides an up-to-date overview
of the regulatory mechanisms of human IgE synthesis.
 
I
 
MMUNOGLOBULIN
 
 
 
EXPRESSION
 
 
 
DURING
 
 B 
 
CELL
 
 
 
DIFFERENTIATION
 
The primary function of B cells is to produce antibodies,
including the IgE isotype, against a vast array of environ-
mental antigens. The production of such a large spec-
trum of antibodies is due to the generation of a large
repertoire of B cells, each of which expresses antibodies
of a different specificity.
Antibody molecules are composed of paired heavy
and light chains and their variable regions have a unique
antigen-binding specificity. Of clonally diverse B cells, a
cell bearing a particular Ig receptor responds to the com-
plementary antigen with proliferation and differentiation
into antibody secreting plasma cells.
The B-lineage cells, which derive from hemopoietic
stem cells that give rise to cells of other blood lineages,
can be divided into five general stages of differentiation
represented by pro-B cells, pre-B cells, immature B cells,
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mature B cells and plasma cells (Fig. 1). The generation
of B cells and their maturation in the bone marrow are
antigen-independent processes, whereas the terminal
differentiation of mature B cells into plasma cells in lym-
phoid organs is antigen dependent.
The production of B cells by the bone marrow is a
multifocal process that involves the generation of an
extensive repertoire of Ig specificities. Such a repertoire is
acquired by a series of gene rearrangements of the vari-
able regions of the Ig heavy and light chains.
 
1,2
 
 Although
pro-B cells start to synthesize cytoplasmic 
 
µ
 
 heavy chains,
but not the conventional light chains of the 
 
κ
 
 or 
 
λ
 
 type
necessary for the formation of a complete IgM molecule,
the cells constitutively express recombination-activating
gene-1 and -2, the products of which (RAG-1 and
RAG-2, respectively) initiate V (variable)–D (diversity)–J
(joining) recombination at the 
 
µ
 
 chain locus. Subse-
quently, these two gene products expressed in pre-B cells,
which express both 
 
µ
 
 chains and surrogate light chains,
initiate V-J recombination at the light chain loci, thereby
leading to the formation of completed IgM molecules
and pre-B cell transition into immature B cells bearing
surface IgM. These cells further differentiate into mature
B cells that coexpress IgD, having identical binding
specificity.
Mature B cells respond to antigens by undergoing
plasma cell differentiation. This terminal differentiation
process involves isotype switching, which allows expres-
sion of IgG, IgA or IgE.
 
3
 
 The generation of switched
B cells and their differentiation are dependent on T cell
help, which is mediated through cytokines and cell
surface molecules provided by activated T cells. Re-
expression of RAG-1 and RAG-2 is also inducible in
mature B cells under suitable conditions before isotype
switching, which is predicted to allow secondary rear-
rangements leading to Ig receptor revision.
 
4
 
 Isotype
switching results from Ig gene rearrangement that involves
the deletion of constant region genes upstream of the
one to be expressed. Thus, individual plasma cells
produce antibodies of a single isotype.
 
Fig. 1
 
B cell differentiation pathway and immunoglobulin gene rearrangements. Cell surface molecules indicate immunoglobulins
expressed during B cell differentiation. H, heavy chain; L, light chain; SL, surrogate light chain; V(D)J, variable (diversity) joining.
 REGULATION OF IgE SYNTHESIS 3
 
Cellular events in the induction of IgE 
synthesis
 
Cognate interactions between B and T cells are required
to induce allergen-specific IgE synthesis (Fig. 2). When a
mature B cell recognizes a particular allergen via B cell
receptor, the cell processes the allergen and presents its
T cell epitope, together with major histocompatibility
complex (MHC) class II molecules, to an allergen-
specific CD4
 
+
 
 T cell with a Th2 phenotype. Subse-
quently, the T cell is activated through engagement of
the 
 
αβ
 
 T cell receptor–CD3 complex and is induced to
produce Th2-type cytokines, such as interleukin (IL)-4
and IL-13, and to express CD40 ligand (CD40L,
CD154), which belongs to the tumor necrosis factor
superfamily. In the presence of T cell-derived IL-4 or
IL-13, the B cell undergoes germline C
 
ε
 
 transcription,
which is a critical initiating step for switching from IgM to
IgE. This cytokine-dependent transcription directs switch-
ing to the corresponding isotype.
 
5–7
 
Signaling through the IL-4 receptor 
 
α
 
 chain (IL-4R
 
α
 
,
CD124), which is a component of both the heterodimeric
IL-4R consisting of the IL-4R
 
α
 
 and the common 
 
γ
 
 chain
(
 
γ
 
c, CD132) and the heterodimeric IL-13R consisting of
the IL-4R
 
α
 
 and IL-13R
 
α
 
1 (CD213a1), plays a key role in
the induction of germline C
 
ε
 
 transcription.
 
8–10
 
 In support
of this is the finding that B cells of X-linked severe com-
bined immunodeficiency patients with mutations in the
 
γ
 
c gene can express germline C
 
ε
 
 transcripts in response
to IL-4 or IL-13.
 
11,12
 
 CD40L, a non-covalent trimer
expressed on the activated T cell, in conjunction with IL-4
or IL-13, not only enhances cytokine-dependent germline
C
 
ε
 
 transcription, but also induces IgE isotype switching
through cross-linking of CD40 constitutively expressed on
the B cell. Engagement of CD40 by CD40L also medi-
ates rescue from apoptosis, proliferation and terminal dif-
ferentiation into IgE antibody secreting plasma cells.
 
13,14
 
Thus, IL-4R
 
α
 
 and CD40 signaling pathways are inte-
grated to induce IgE isotype switching and IgE synthesis.
The central role of the interaction of CD40 with
CD40L in switching to T cell-dependent isotypes has
been shown in patients with X-linked hyper-IgM syndrome
who have mutations in the CD40L gene that result in
defective isotype switching.
 
15
 
 Although CD40 on B cells
prompts endocytosis of surface CD40L expressed on acti-
vated T cells, engagement of CD40L by CD40 is able
to increase IL-4 production by T cells, thereby leading
to enhanced germline C
 
ε
 
 transcription.
 
16,17
 
 This may
Fig. 2 Induction of allergen-
specific IgE synthesis by cognate
interactions between B and
T cells. BCR, B cell receptor;
CD40L, CD40 ligand; IL, inter-
leukin; IL-4/IL-13R, receptor for
IL-4 or IL-13; MHC II, major
hisotocompatibility complex
class II molecules; TCR, α/β
T cell receptor.
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contribute to upregulation of IgE isotype switching and
IgE synthesis.
In addition to CD4
 
+
 
 T cells with a Th2 phenotype,
CD8
 
+
 
 T cells with a Tc2 phenotype, CD3
 
+
 
 T cells bearing
the 
 
γδ
 
 T cell receptor, mast cells, basophils and eosi-
nophils produce IL-4 and/or IL-13 and express CD40L
after immunologic or non-immunologic stimulation.
 
18–22
 
Such cellular responses allow adjacent B cells to induce
IgE isotype switching and differentiation into IgE-
secreting plasma cells.
More recently, glucocorticoids have been shown to
upregulate CD40L expression both in T and B cells.
 
23
 
Thus, several cell types are involved in the induction of
IgE synthesis, although the production of specific IgE anti-
body by a given B cell clone is critically dependent on the
interaction with an allergen-specific CD4
 
+
 
 T cell. In con-
trast, other lineage cells may participate mainly in poly-
clonal IgE production by different B cells.
 
M
 
OLECULAR
 
 
 
MECHANISMS
 
 
 
OF
 
 I
 
G
 
E 
 
ISOTYPE
 
 
 
SWITCHING
 
A mature B cell can switch the Ig class while retaining
the same antigen specificity. This event results from
isotype switching that occurs by a DNA rearrangement in
the C
 
H
 
 (constant region of the heavy chain) gene
locus.
 
3,24
 
 The human 
 
C
 
H
 
 gene family consists of nine
functional genes and two pseudogenes. The organiza-
tion of the C
 
H
 
 locus located at the 3
 
′
 
 side of a given V
 
H
 
segment, a D segment and a J
 
H
 
 segment that complete
a V
 
H
 
 region sequence is as follows: 5
 
′
 
-J
 
H
 
-C
 
µ
 
-C
 
δ
 
-C
 
γ
 
3-
C
 
γ
 
1-C
 
ψε
 
-C
 
α
 
1-C
 
ψγ
 
-C
 
γ
 
2-C
 
γ
 
4-C
 
ε
 
-C
 
α
 
2-3
 
′
 
 (Fig. 3a). A
DNA recombination involved in isotype switching takes
place between two switch (S) regions located at the
5
 
′
 
 side of each 
 
C
 
H
 
 gene, except C
 
δ
 
 and C
 
ψγ
 
.
 
25
 
 The
S regions include S
 
µ
 
, S
 
γ
 
, S
 
α
 
 and S
 
ε
 
, each of which is
composed of tandem repeats of short unit sequences.
Although the Sε region is also present before the Cψε
gene, this region is not involved in recombination
because of the defect in a part of the exon. Furthermore,
the germline IH exons (Iµ, Iγ, Iα and Iε) are located 5′ to
each functional S region. With the exception of constitu-
tive activation of the Iµ promoter, the other IH promoter
is activated in response to appropriate cytokines, result-
ing in transcription of the IH exon, the S region and the
CH exons. Because transcripts of the S region are spliced
out by splicing factors, the resultant IH and CH transcripts
are germline CH transcripts, expression of which directs
Fig. 3 Molecular events involved in IgE isotype switching. (a) Organization of nine functional genes and two pseudogenes of CH
isotypes. The functional Cε gene is located between the Cγ4 gene and the Cα2 gene. (b) Interleukin (IL)-4- or IL-13-dependent
germline Cε transcription and CD40 ligand (CD40L)-dependent switching from IgM to IgE. See text for details.
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isotype switching by regulating the accessibility of a
particular S region to a putative common recombinase
system.5,26 This type of recombination involves the Sµ
region as one of the pair and the Sγ, Sα or Sε region is
involved as the other partner, resulting in the activation
of switch recombination responsible for the induction of
switching from Cµ to Cγ, Cα or Cε.
Engagement of CD40 by CD40L in the presence of a
particular cytokine plays a crucial role in a given switch
recombination.3,14,27 During recombination, the DNA
segment between the expressed VH and CH genes is
looped out as a circle and deleted from the chromosome.
Although the switch recombinase has not as yet been
identified, activation-induced cytidine deaminase (AID),
a B cell-specific RNA-editing enzyme, has recently been
reported to be expressed after cytokine and CD40L stim-
ulation and to be involved in regulation or catalysis of the
DNA modification step of isotype switching.28–30 Actually,
AID deficiency causes the autosomal recessive form of
the hyper-IgM syndrome30 characterized by defective
DNA switch recombination.
During an IgE response, IL-4- or IL-13-dependent
induction of germline Cε transcription precedes CD40-
mediated Sµ–Sε recombination (Fig. 3b). Activation of
the Iε promoter, which contains an IL-4 or IL-13 response
element, initiates transcription of the Iε exon, the Sε
region and the Cε1–4 exons. Subsequently, splicing cuts
the transcript of the Sε region, thereby allowing expres-
sion of germline Cε transcripts. Several studies have
shown that spliced switch transcripts bind the DNA of the
corresponding S region and induce stable RNA/DNA
hybrids that are a target for both a ribonuclease and a
switch recombinase.5,6,26 Thus, processing of germline Cε
transcripts may be of importance in directing Sµ–Sε
recombination.
CD40 ligation not only upregulates IL-4- or IL-13-
driven germline Cε transcription due to full activation of
the Iε promoter, but also induces expression of AID,
which plays a role downstream of the germline Cε tran-
scription. Activation-induced cytidine deaminase expres-
sion is followed by activation of the recombination
machinery that allows the deletion of the intervening DNA
between the Sµ region and the targeted Sε region. This
deletional recombination results in the juxtaposition of
the Cε gene to the expressed gene of the variable region
and in the subsequent induction of mature Cε transcrip-
tion and IgE synthesis. In addition, alternative splicing is
involved in the transition from the membrane to the
secreted form of IgE.
SIGNAL TRANSDUCTION OF IL-4 AND IL-13
The pleiotropic activities of IL-4 and IL-13 in B cells are
ascribed to the ability of these cytokines to mediate a
diverse array of functions, including induction of germ-
line Cε transcription and enhanced expression of CD23,
CD86 and MHC class II molecules.9–11 Such over-
lapping activities arise from using the IL-4Rα that forms
a heterodimeric complex with either the γc or the
IL-13Rα1. Although these three receptor chains lack the
intrinsic tyrosine kinase domain, IL-4 and IL-13 induce
tyrosine phosphorylation of several cellular proteins.
Many cytokines activate members of the Janus kinase
(JAK) family, resulting in activation of members of the
signal transducer and activator of transcription (STAT)
family.31 The IL-4Rα, γc and IL-13Rα1 associate with
JAK1, JAK3 and TYK2, respectively. Ligand binding
activates these JAK, which, in turn, induces phosphoryla-
tion of STAT-6 recruited to the IL-4Rα. Furthermore, the
phosphorylated STAT-6 forms a homodimer via its Src
homology (SH) 2 domain, translocates to the nucleus
and binds to the consensus sequence present in the
promoter regions of the IL-4- or IL-13-responsive genes.
These regions include the Iε promoter, activation of
which leads to induction of germline Cε transcription.
Extensive studies have shown that the Iε promoter
contains binding elements for STAT-6, CCAAT/enhancer-
binding protein (C/EBP), nuclear factor (NF)-κB and
B cell-specific activator protein (BSAP, Pax-5).32–36 In
addition, the upstream NF-κB site overlaps with a
binding element for PU.1, a product of the ets proto-
oncogene family.36 The essential role of STAT-6 in
germline Cε transcription and IgE isotype switching
is well established. Interestingly, a genetic variant of
IL-4Rα, namely Ile50Val, has been identified in relation
to atopic asthma, associates with IL-4 or IL-13 activity
and upregulates STAT-6 activation.37,38
In addition to the JAK–STAT pathway, other pathways
are involved in the activation of the Iε promoter. The
IL-4Rα associates with adaptor molecules, such as insulin
recepor substrate (IRS)-1, IRS-2, Src homologous and
collagen (Shc) and IL-4 receptor-interacting protein
(FRIP) and the products of the fes proto-oncogene family
(FES and FER),39–42 and these molecules transmit the
downstream signaling (Fig. 4). Although FRIP is not
expressed in B cells, other molecules are constitutively
expressed in many cell types, including B and T cells. Both
IRS-1/2 and Shc bind to the insulin/IL-4R (I4R) region of
the IL-4Rα. This region contains an Asn-Pro-X-Tyr (NPXY)
6 Y YANAGIHARA
motif that specifically interacts with the phosphotyrosine-
binding (PTB) domain of IRS-1/2 or Shc.39,44 In contrast,
FES/FER contains the coiled-coil regions that are able to
interact with the region located between the Box1 and the
I4R.41 Among these adaptor molecules, IRS-1/2 and
FES/FER contain the conserved Tyr-X-X-Met (YXXM)
motif to which the SH2 domain of phosphatidylinositol
3-kinase (PI3K) binds. Furthermore, FER, but not FES, is
selectively expressed in mature B cells.41 Although IRS-1/
2-dependent activation of PI3K has been most extensively
studied in many cell types, FER can mediate PI3K activa-
tion in mature B cells, independently of IRS-1/2.43 There-
fore, it is possible that, in B cells, Shc rather than IRS-1/2
preferentially binds to the NPXY motif of the I4R region.
This possibility is supported by the finding that recom-
binant Shc can bind to a phosphopeptide identical to the
I4R region, despite the negligible sequence homology
between the PTB domain of IRS-1/2 and that of Shc.44,45
Although Shc mediates activation of phospholipase Cγ1
(PLCγ1) through direct association, the initial production
of inositol 1,4,5-trisphosphate is marginal, thus resulting
in no significant change in intracellular Ca2+ levels.43
This contrasts with the high and prolonged production
of 1,2-diacylglycerol (DAG). Both the lipid product of
PI3K activated through FER and DAG generated through
Shc-dependent PLCγ1 activate isozymes of protein kinase C
(PKC), the substrates of which include transcription
factors that cooperate functionally with STAT-6 (Fig. 5).
Isozymes of PKC can be classified into four groups
according to endogeneous and exogeneous activators:
(i) conventional PKC (α, β1, β2 and γ), which depend on
both Ca2+ and DAG; (ii) novel PKC (δ, ε, θ and η), which
are Ca2+ independent and regulated by DAG; (iii) atypi-
cal PKC (ζ and ι/λ), which require neither Ca2+ nor
DAG; and (iv) PKCµ that has a putative transmembrane
domain.46 Moreover, both novel and atypical PKC iso-
zymes are activated by the lipid products of PI3K. Among
these, the Ca2+-independent isozymes PKCδ and PKCζ
are specifically activated in response to IL-4 or IL-13 and
can mediate threonine phosphorylation of PU.1.24,47
Although binding elements for C/EBP, NF-κB and BSAP
are also present in the Iε promotor, none of these tran-
scription factors is susceptible to PKCδ and PKCζ. Thus,
two such PKC isozymes appear to regulate transactiva-
tion by PU.1. Indeed, activation of the Iε promotor by
IL-4 and IL-13 can be blocked not only by dominant
negative mutants of PKCδ and PKCζ, but also by
isozyme-specific inhibitors rottlerin and PKCζ pseudo-
substrate peptide.47 However, these mutants and inhibi-
tors do not affect tyrosine phosphorylation and DNA
Fig. 4 Association of several molecules with the intracellular domain of the interleukin (IL)-4 receptor α chain. Of these molecules,
insulin receptor substrate (IRS), Src homologous and collagen (Shc), IL-4 receptor interaction protein (FRIP) and the products of the
fes proto-oncogene family (FES/FER) are adaptor molecules containing the phosphotyrosine-binding (PTB) domain that binds to an
Asn-Pro-X-Tyr (NPXY) motif present in the insulin/IL-4 receptor (I4R) region. Only FRIP is not expressed in B cells. Both IRS-1/2 and
FES/FER contain the conserved Tyr-X-X-M (YXXM) motif to which the Src-homology (SH) 2 domain of phosphatidylinositol 3-kinase
binds. The Box1 region is critical for the constitutive association with Janus kinase (JAK) 1 containing the JAK homology (JH) domains
and a protein tyrosine kinase (PTK) sequence. CC, coiled-coil region; CH, collagen homology domain; TM, transmembrane region;
PH, pleckstrin homology (PH) domain.
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binding activity of STAT-6. Several lines of evidence
support the notion that PU.1, as well as NF-κB, coopa-
rates with STAT-6 for the synergistic activation of the Iε
promotor.34,36,48,49
SIGNAL TRANSDUCTION THROUGH CD40
Ligation of CD40 on B cells upregulates IL-4- or IL-13-
driven germline Cε transcription and activates DNA
switch recombination that leads to IgE isotype switching,
mature Cε transcription and IgE synthesis. The cyto-
plasmic domain of CD40, which lacks any motifs for
transducing signals into B cells, associates not only with
two tyrosine kinases (Lyn and JAK3), but also with four
members of the six known tumor necrosis factor receptor-
associated factor (TRAF) family proteins, namely TRAF2,
TRAF3, TRAF5 and TRAF6.50–53 These molecules can
mediate activation of transcription factors, such as
STAT-3 and NF-κB. In particular, NF-κB cooperates
with STAT-6 and thereby contributes to the increased
activity of the Iε promotor. However, none of the known
transcription factors activated through CD40 ligation is
critical for isotype switching that results from loop-out
and deletional recombination. Isotype switching requires
AID, expression of which is dependent on a combination
of cytokine stimulation and CD40 ligation.29,30 This
novel enzyme appears to play a role upstream of the
putative switch recombinase (Fig. 6). Furthermore, Ku70
and Ku80, which form a heterodimer and are associated
with CD40, are required to perform switch recombina-
tion.54–56 This heterodimer is dissociated from the CD40
following cytokine stimulation and CD40 ligation, trans-
locates into the nucleus and binds to the DNA-dependent
protein kinase. Such a heterotrimeric complex, as well as
DNA ligase IV, is involved in the repair of double-strand
breaks. Thus, CD40 signaling activates multiple path-
ways that are important for both the enhancement of
germline Cε transcription and the induction of IgE
switching.
Fig. 5 Signal transduction path-
ways of interleukin (IL)-4 and
IL-13 for the activation of the Iε
promoter that results in germline
Cε transcription. Ligand binding
activates not only the Janus
kinase (JAK)-dependent signal
transducer and activator of tran-
scription (STAT) pathway, but
also the adaptor molecule-
dependent pathway. BSAP, B cell-
specific activator protein; C/EBP,
CCAAT/enhancer-binding pro-
tein; DAG, 1,2-diacylglycerol;
FER, a product of the fes proto-
oncogene family; IL-4Rα, IL-4
receptor α chain; IL-13Rα1,
IL-13 receptor α1 chain; NF-κB,
nuclear factor-κB; PI3,4,5-P3,
phosphatidylinositol 3,4,5-tri-
phosphate; PI3K, phosphati-
dylinositol 3-kinase; PLCγ1,
phospholipase Cγ1; PKC, pro-
tein kinase C; PU.1, a product of
the ets proto-oncogene family;
γc, common γ chain; Shc, Src
homologous and collagen; TYK2,
tyrosine kinase 2.
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CD40 ligation-derived signals enhance IL-4- or IL-13-
driven germline Cε transcription. One such signal is
NF-κB, which synergizes with STAT-6 on the Iε promoter
for enhanced DNA-binding affinity.34,36,48 Among the
TRAF proteins associated with CD40, TRAF2, TRAF5 and
TRAF6 mediate activation of NF-κB through their ability
to bind activators of the IκB kinase complex.53,57 How-
ever, TRAF-dependent NF-κB activation appears to be
cell type specific. In B cells, TRAF6 is of importance in
activating NF-κB and exerts an enhancing effect on
germline Cε transcription.53 Furthermore, TRAF3 is
involved in upregulating germline Cε transcription in a
manner that is independent of NF-κB activation. This may
be mediated through TRAF3-dependent activation of
mitogen-activated protein kinase (MAPK)/extracellular
signal-regulated kinase (ERK) kinase 1 (MEK1).58 Actu-
ally, like PD98059, a specific inhibitor of MEK1, selective
abrogation of constitutive expression of TRAF3 protein by
antisense oligodeoxynucleotide for TRAF3 inhibits CD40-
mediated ERK activation, resulting in decreased germline
Cε transcription.58 However, the downstream events that
arise from TRAF3-dependent ERK activation remain
unclear.
Although at least TRAF3 and TRAF6 are important for
CD40-mediated enhancement of germline Cε transcrip-
tion, none of the TRAF proteins is involved directly in
CD40-mediated IgE switching. CD40 ligation also medi-
ates activation of tyrosine kinases, including Lyn and
JAK3. The finding that tyrosine kinase inhibitors, such as
genistein and herbimycin A, inhibit CD40-mediated
isotype switching suggests that tyrosine kinase activity
may contribute to the activation of the switch recombina-
tion machinery system.59 However, neither Lyn nor JAK3
is critical in isotype switching, because B cells of JAK3-
deficient patients have the ability to switch to IgE and
because Lyn, as well as JAK3, is also associated with
other receptors.59 Despite great efforts, the nature of the
tyrosine kinase(s) involved in CD40-mediated switch
recombination has not yet been defined. It is also cur-
rently unclear whether CD40 signaling pathway for the
Fig. 6 Involvement of activation-induced cytidine deaminase (AID) in IgE isotype switching. Expression of AID induced by stimula-
tion with interleukin (IL)-4/IL-13 and CD40 ligand is a critical step for the activation of the putative switch recombinase. The same
stimulation also induces formation of a heterotrimeric complex composed of Ku70, Ku80 and DNA-dependent protein kinase (PK).
This heterotrimer, as well as DNA ligase IV, is involved in the repair of double strand breaks, which is required to perform switch
recombination. VDJ, variable–diversity–joining segment.
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upregulation of germline Cε transcription and that for
the induction of AID expression and IgE switching are
overlapping or totally different.
PHARMACOLOGIC REGULATION OF B CELL 
DIFFERENTIATION INTO IGE-SECRETING 
PLASMA CELLS
Several attempts have been made to regulate germline
Cε transcription and IgE synthesis. Cytokine-dependent
induction of germline Cε transcription is inhibited by
neutralizing antibodies against IL-4 or IL-13, a soluble
form of the IL-4Rα or IL-13Rα1/α2 and a single or
double mutant of IL-4.60,61 In addition to these antibod-
ies and antagonists, agents that prevent IL-4Rα signaling
inhibit germline Cε transcription. Such agents include
not only interferon (IFN)-γ itself or inducers of IFN-γ
production, but also inhibitors of PKCδ and PKCζ that
are activated through adaptor molecules associatd with
the IL-4Rα.47,62 Activation of IFN-γR induces expression
of a negative regulator of JAK-dependent STAT-6 acti-
vation.62 As for IL-12- or IL-18-dependent IFN-γ pro-
duction, the predominant expression of a 91 base
deletion of the IL-12Rβ2 cDNA or a three base deletion
of the IL-18Rα cDNA is associated with reduced IFN-γ
production in some allergic patients with high serum IgE
levels.63,64 Thus, therapy with inducers of IFN-γ pro-
duction will limit their usefulness in allergic patients
without such a deletion of the cytokine receptor cDNA.
Although abrogation of CD40 signaling can be targeted
by inhibiting switch recombination, this abrogation leads
to non-specific suppression of isotype switching. Thus,
strategies that target the merging point of IL-4Rα and
CD40 signaling pathways would be desirable. Because
allergic individuals have some B cells that have already
switched to IgE in vivo, therapy directed towards IgE-
expressing B cells also needs to regulate the terminal
differentiation into IgE-secreting plasma cells. In this
respect, a therapeutic approach using potent IgE-binding
agents, such as a soluble form of the high-affinity IgE
receptor α subunit (soluble FcεRIα) and anti-IgE anti-
bodies, may be useful in inactivating or eliminating IgE-
expressing B cells.
Both soluble FcεRIα and anti-IgE antibodies can selec-
tively modulate IgE synthesis by binding to IgE-expressing
B cells.65,66 Although the membrane-bound form of IgE
is a common target for these agents, regulation of IgE
synthesis by soluble FcεRIα differs entirely from that by
anti-IgE antibodies. For instance, soluble FcεRIα inhibits
IgE synthesis via monovalent recognition of membrane
IgE, whereas F(ab′)2 but not Fab fragments of anti-IgE
antibodies have an inhibitory effect.65,66 The latter finding
indicates that inhibition of IgE synthesis by anti-IgE anti-
bodies requires divalent recognition of membrane IgE.
Furthermore, there is a marked difference between mech-
anisms for soluble FcεRIα- or anti-IgE antibody-induced
inhibition of IgE synthesis.67 Binding of soluble FcεRIα to
IgE-expressing B cells leads to a decrease in the autocrine
production of IL-6, which provides a late amplification
signal for IgE synthesis.67 In contrast, anti-IgE antibodies
or their F(ab′)2 fragments induce apoptosis in IgE-
expressing B cells, although neither their Fab fragments
nor soluble FcεRIα have such apoptotic activity. Thus,
cross-linking of membrane IgE is able to induce apop-
tosis, which accords with a report describing that anti-IgE
antibodies were effective in downregulating expression of
Bcl-2, known to inhibit apoptotic cell death.68 These data
suggest that both soluble FcεRIα and anti-IgE antibodies
may be useful in inhibiting the terminal differentiation of
IgE-expressing B cells, including memory cells, into IgE-
secreting plasma cells. In particular, non-anaphylactogenic
humanized or chimeric anti-IgE monoclonal antibodies
have been produced that bind to free IgE and membrane
IgE but not to IgE bound to the cell surfact FcεRI.69–72
These properties are similar to those of soluble FcεRIα,
which traps IgE via its Cε3 domain responsible for recep-
tor binding.
CONCLUSIONS
Allergen-specific IgE synthesis contributes to the induc-
tion and maintenance of allergic symptoms. The expo-
tential increase in the understanding of the cellular
mechanisms of IgE synthesis has led to the development
and clinical trials of agents capable of regulating the
differentiation of B cells into IgE-secreting plasma cells.
However, the molecular mechanisms involved in IgE
isotype switching are incompletely understood. Although
AID appears to be an essential part of the switch
recombination machinery, the switch recombinase has
not, as yet, been identified. Elucidation of the merging
point of IL-4Rα and CD40 signaling pathways that are
required for AID expression and IgE switching, as well as
identification and characterization of the switch recombi-
nase, are the next challenge for future studies and
should provide potential new strategies for the isotype-
specific regulation of IgE synthesis.
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